CFCM Daily Radar — CD24, CAR-T Resistance, Cytometry AI and ETP-ALL

Paper of the Day — CD24 targeting after CD19 CAR-T resistance

Peer-reviewed original research

Qing Yin, Jing Gao, Xiangao Huang, Allen Hu, Rui Xiong and colleagues. Combating CD24 to overcome CD19 CAR-T resistance via induction of innate and adaptive immunity in B-cell malignancies. Leukemia. Published 12 October 2026. DOI: 10.1038/s41375-026-03159-y.

The study evaluates CD24-directed bispecific antibodies, CAR-T strategies and dual CD19/CD24 approaches in experimental B-cell malignancy models. CD24-directed activity persisted in models with CD19 antigen loss, and macrophage phagocytosis increased in functional experiments. These are preclinical findings, not evidence of clinical efficacy.

Why it matters to CFCM: target-antigen monitoring cannot stop at a single lineage marker. Antigen heterogeneity, escape after therapy and functional immune effects all affect how flow results should be interpreted.

AI & Technology Radar — CytoDNNEnsemble

Peer-reviewed computational research

Tomasz Gniazdowski and Urszula Markowska-Kaczmar. CytoDNNEnsemble: combining cell-level and distribution-level representations for flow-cytometry classification. Scientific Reports. Published 12 October 2026. DOI: 10.1038/s41598-026-74128-9.

The architecture combines cell-level and sample-distribution representations. Performance improved on some public benchmarks but remained dataset-dependent. Benchmark classification accuracy is not equivalent to clinical validation or rare-event MRD performance.

CFCM placement: Intelligence → AI & Technology Radar; Academy → Automated Analysis.

Pediatric monocytic AML — MRD remains prognostically relevant

Peer-reviewed retrospective clinical research

Clinical Outcomes and Prognostic Factors in Pediatric Acute Myeloid Leukemia with Monocytic Differentiation: A Single-Center Cohort Study from Egypt. Frontiers in Oncology. DOI: 10.3389/fonc.2026.1969723.

MRD positivity after first induction was independently associated with poorer outcomes. For CFCM, the key teaching point is analytical: monocytic maturation can complicate abnormal-versus-regenerating population discrimination, so thresholds should never be transplanted between laboratories without validating the full assay context.

CFCM placement: News → AML; Academy → MRD and Monocytic Differentiation.

Academy — ETP-ALL phenotype does not define the whole biology

Peer-reviewed review article

Hee Young Ju. Understanding and clinical approach to early T-cell precursor acute lymphoblastic leukemia. Blood Research. Published 12 October 2026. DOI: 10.1007/s44313-026-00181-y.

The review emphasizes how an immature ETP immunophenotype remains clinically useful while failing to capture all molecular diversity. MRD response remains central to risk assessment.

CFCM placement: Academy → T-ALL / ETP-ALL; Resources → Haematological Malignancy Reviews.

Evidence note

The featured CD24 work is preclinical. CytoDNNEnsemble is an algorithmic evaluation, not a clinical deployment study. The pediatric AML findings are retrospective and the ETP-ALL item is a literature review.